Thinking about what to do with Eli Lilly shares? You’re certainly not alone. The stock has been climbing the leaderboard for ...

The FDA typically follows the recommendations of its advisory panels but is not required to do so. If cleared for use, Eli Lilly's donanemab would become the second Alzheimer's drug of its kind ...

Labcorp plans to offer Roche’s recently FDA-cleared blood test to assess early signs of Alzheimer’s disease and other causes ...

This comes at the heel of FDA's nod for Fujirebio Diagnostics' blood test Lumipulse in May, the first such device to get approval to diagnose the brain-wasting condition. It is intended for patients ...

A new blood test that could help doctors identify whether a patient has Alzheimer’s disease was cleared by the FDA last week.

Eli Lilly and Company (NYSE:LLY) is one of the stocks to invest in before they split next. On September 9, Eli Lilly and Company launched a new global campaign titled “Brain Health Matters” to ...

Eli Lilly and Company LLY reported third-quarter 2025 adjusted earnings per share (“EPS”) of $7.02, which beat the Zacks ...

Macquarie Asset Management, an investment management company, released its “Macquarie Large Cap Growth Fund” investor letter for the second quarter of 2025. A copy of the letter can be downloaded here ...

October 30th is the day when Eli Lilly will report its third-quarter results, including sales of its 'superstars' Zepbound ...

Eli Lilly and Company (LLY), headquartered in Indianapolis, Indiana, is a leading global pharmaceutical company dedicated to ...

Get the latest on Novo Nordisk's Alzheimer's trial, stock outlook, and market risks. See what investors need to know before ...